Harfst & Associates Inc. Makes New Investment in Danaher Corporation $DHR

Key Points

• Harfst & Associates Inc. acquired 3,298 shares of Danaher Corporation, valued at approximately $676,000, during the first quarter, marking a notable addition to institutional ownership which is at 79.05%.
• Danahar has seen significant ratings changes from analysts, with three hold ratings and eighteen buy ratings, leading to a consensus target price of $247.61.
• In the latest earnings report, Danaher exceeded consensus estimates, reporting $1.80 earnings per share and year-over-year revenue growth of 3.4%.

Harfst & Associates Inc. purchased a new position in shares of Danaher Corporation (NYSE:DHR - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 3,298 shares of the conglomerate's stock, valued at approximately $676,000.

Several other hedge funds and other institutional investors have also made changes to their positions in DHR. Nuveen LLC acquired a new position in shares of Danaher during the 1st quarter worth $833,941,000. GAMMA Investing LLC raised its stake in shares of Danaher by 24,958.2% during the 1st quarter. GAMMA Investing LLC now owns 1,870,847 shares of the conglomerate's stock worth $383,524,000 after buying an additional 1,863,381 shares during the last quarter. Two Sigma Advisers LP raised its stake in shares of Danaher by 4,248.8% during the 4th quarter. Two Sigma Advisers LP now owns 1,639,500 shares of the conglomerate's stock worth $376,347,000 after buying an additional 1,601,800 shares during the last quarter. Capital World Investors raised its stake in shares of Danaher by 32.7% during the 4th quarter. Capital World Investors now owns 6,361,183 shares of the conglomerate's stock worth $1,460,215,000 after buying an additional 1,566,658 shares during the last quarter. Finally, Invesco Ltd. raised its stake in Danaher by 44.5% in the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock valued at $965,259,000 after purchasing an additional 1,450,703 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.

Danaher Trading Up 1.4%

Shares of NYSE:DHR traded up $3.0150 during trading on Tuesday, reaching $212.0250. 1,682,568 shares of the stock were exchanged, compared to its average volume of 4,220,352. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $279.90. The firm has a market cap of $151.82 billion, a price-to-earnings ratio of 45.05, a price-to-earnings-growth ratio of 2.94 and a beta of 0.73. The firm's 50-day moving average price is $200.14 and its 200 day moving average price is $199.45.

Danaher (NYSE:DHR - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The business had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. During the same quarter in the previous year, the business earned $1.72 EPS. The company's revenue for the quarter was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, sell-side analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Robert W. Baird boosted their target price on shares of Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a research note on Friday, July 18th. Jefferies Financial Group cut their target price on shares of Danaher from $260.00 to $230.00 and set a "buy" rating for the company in a research note on Tuesday, April 22nd. JPMorgan Chase & Co. cut their target price on shares of Danaher from $280.00 to $260.00 and set an "overweight" rating for the company in a research note on Tuesday, April 22nd. The Goldman Sachs Group cut their target price on shares of Danaher from $260.00 to $240.00 and set a "neutral" rating for the company in a research note on Wednesday, April 23rd. Finally, Royal Bank Of Canada reissued an "outperform" rating and issued a $250.00 target price on shares of Danaher in a research note on Wednesday, April 23rd. Seventeen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $247.61.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.